CMPI Report: Principles for Patient-Centered Prescription Drug Coverage


Read the Report here.


Principles for Patient-Centered Prescription Drug Coverage

Monday, September 11, 2017  
8:30am – 1:30 pm
National Press Club
Holeman Lounge
529 14th St NW
Washington, DC 20045
 
Panel One:     How PBMs Affect Access and Affordability
 
Moderator:     Peter J. Pitts, President, CMPI
Panelists:         B. Douglas Hoey, CEO, National Community Pharmacists Association
                          Nick Ferreyros, Director of Communications, Community Oncology Alliance
                          Derek Daggett, Senior Business Development Executive, SmithRx

Watch Panel One highlights here.

Keynote Speaker: A. Mark Fendrick, M.D., Director, Center for Value Based Insurance Design, University of Michigan
Introduction by Robert M. Goldberg, CMPI

Watch Dr. A. Mark Fendrick's Keynote Remarks here.

Panel Two:     Principles for PBM Reform and Patient-Centered Prescription Drug Benefits
 
Moderator:   Robert M. Goldberg, PhD, Vice President, CMPI
Panelists:       Shawn Lovering, President, RxTE
                        Susan Pilch, Vice President, Policy & Regulatory Affairs, NCPA
                        A. Mark Fendrick, M.D., University of Michigan
                        Burt Zweigenhaft, Managing Partner, Upstream Partners
 
Watch Panel Two highlights here.
Sign Up for Our Email Newsletter

RECENT NEWS

Understanding the FDA's Take on Cannabidiol

Understanding the FDA's Take on Cannabidiol

If you're a cancer patient, you are no stranger to pain or, most likely, to opioids....  Read more

Elizabeth Warren's Threat to Medical Progress

Elizabeth Warren's Threat to Medical Progress

Senator Elizabeth Warren (D-MA) mistakenly believes that pharmaceutical innovation is primarily driven by the National In...  Read more

It’s time to get serious about the economics of expanded access

It’s time to get serious about the economics of expanded access

One of the most significant issues is the silent elephant in the room: Who should pay for access to experimental medicine...  Read more

DRUGWONKS BLOG